# US 2014/0154229 A1 · Proteolytic extract from bromelain for the treatment of connective tissue disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154229 A1
- Document ID: US20140154229A1
- Status: Published application
- Kind: A1
- Application number: 14/233,082
- Filed: 2012-07-19
- Published: 2014-06-05
- Earliest claimed: 2011-07-20
- Assignees: MediWound Ltd.
- Inventors: Lior Rosenberg; Guy Rubin; Eilon Asculai
- Web page: https://patentgrep.com/patent/US20140154229A1

## CPC

- A61K 38/4873: {Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 36/88: Liliopsida (monocotyledons)
- A61K 38/1732: {Lectins}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 23/00: Anaesthetics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- C12Y 304/22031: Ananain (3.4.22.31)
- C12Y 304/22032: Stem bromelain (3.4.22.32)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention relates to a proteolytic extract obtained from bromelain for the treatment of connective tissue diseases. In particular, the present invention relates to a pharmaceutical composition that includes proteolytic extract obtained from bromelain for the treatment of diseases such as Dupuytren's disease and Peyronie's disease.

## Claims

### Claim 1

A method of treating a connective tissue disease comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of a proteolytic extract obtained from bromelain and a pharmaceutically acceptable carrier, wherein the proteolytic extract comprises at least one cysteine protease selected from the group consisting of stem bromelain and ananain, and wherein the connective tissue disease is associated with excess collagen deposition.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the connective tissue disease is selected from the group consisting of Dupuytren's disease, Peyronie's disease, frozen shoulder, and Ledderhose disease.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the connective tissue disease is Dupuytren's disease.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the connective tissue disease is Peyronie's disease.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the proteolytic extract comprises stem bromelain and ananain.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the proteolytic extract further comprises at least one cysteine protease precursor.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition further comprises an agent selected from the group consisting of an anesthetic agent, antibacterial agent and an anti-inflammatory agent.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the anesthetic agent is selected from the group consisting of amethocaine (tetracaine), lignocaine (lidocaine), xylocaine, bupivacaine, prilocaine, ropivacaine, benzocaine, mepivocaine, cocaine and combinations thereof.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the antibacterial agent is selected from the group consisting of amanfadine hydrochloride, amanfadine sulfate, amikacin, amikacin sulfate, amoglycosides, amoxicillin, ampicillin, amsamycins, bacitracin, beta-lactams, candicidin, capreomycin, carbenicillin, cephalexin, cephaloridine, cephalothin, cefazolin, cephapirin, cephradine, cephaloglycin, chilomphenicols, chlorhexidine, chloshexidine gluconate, chlorhexidine hydrochloride, chloroxine, chlorquiraldol, chlortetracycline, chlortetracycline hydrochloride, ciprofloxacin, circulin, clindamycin, clindamycin hydrochloride, clotrimazole, cloxacillin, demeclocycline, diclosxacillin, diiodohydroxyquin, doxycycline, ethambutol, ethambutol hydrochloride, erythromycin, erythromycin estolate, erhmycin stearate, farnesol, floxacillin, gentamicin, gentamicin sulfate, gramicidin, giseofulvin, haloprogin, haloquinol, hexachlorophene, iminocylcline, iodochlorhydroxyquin, kanamycin, kanamycin sulfate, lincomycin, lineomycin, lineomycin hydrochloride, macrolides, meclocycline, methacycline, methacycline hydrochloride, methenine, methenamine hippurate, methenamine mandelate, methicillin, metonidazole, miconazole, miconazole hydrochloride, minocycline, minocycline hydrochloride, mupirocin, nafcillin, neomycin, neomycin sulfate, netimicin, netilmicin sulfate, nitrofurazone, norfloxacin, nystatin, octopirox, oleandomycin, orcephalosporins, oxacillin, oxyteacline, oxytetracycline hydrochloride, parachlorometa xylenol, paromomycin, paromomycin sulfate, penicillins, penicillin G, penicillin V, pentamidine, pentamidine hydrochloride, phenethicillin, polymyxins, quinolones, streptomycin sulfate, tetracycline, tobramycin, tolnaftate, triclosan, trifampin, rifamycin, rolitetracycline, silver salts, spectinomycin, spiramycin, struptomycin, sulfonamide, tetracyclines, tetracycline, tobramycin, tobramycin sulfate, triclocarbon, triclosan, trimethoprim-sulfamethoxazole, tylosin, vancomycin, and yrothricin.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the anti-inflammatory agent is selected from the group consisting of non-steroidal anti-inflammatory agents and steroidal anti-inflammatory agents.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition further comprises a component selected from the group consisting of a stabilizing agent, an anti-oxidant, a preservative, a buffering agent, a chelating agent, and a tonicity agent.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is formulated in a form selected from the group consisting of a solid formulation, a semi solid formulation, a liquid formulation and a foam formulation.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the solid formulation is a powder.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the liquid formulation is an injectable solution of a pH of about 6 to about 7.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is administered by injection into the diseased fibrous tissue.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the pharmaceutical composition is injected as a single dose.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the pharmaceutical composition is injected in aliquots at two or more locations in the diseased fibrous tissue.

### Claim 18

A pharmaceutical composition comprising a proteolytic extract for use in the treatment of a connective tissue disease, wherein the proteolytic extract comprises at least one cysteine protease selected from the group consisting of stem bromelain and ananain, and wherein the connective tissue disease is associated with excess collagen deposition.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18 that includes a pharmaceutically acceptable carrier and further comprises an agent selected from the group consisting of an anesthetic agent, antibacterial agent and an anti-inflammatory agent.

### Claim 20 (depends on 18)

The pharmaceutical composition of claim 18 further comprising a component selected from the group consisting of a stabilizing agent, an anti-oxidant, a preservative, a buffering agent, a chelating agent, and a tonicity agent, with the pharmaceutical composition formulated in a form selected from the group consisting of a solid formulation, a semi solid formulation, a liquid formulation and a foam formulation.
